No Detail Found!

Adalimumab induced psoriasis in a Crohn's disease patient: A case report

Author(s)
Dhaifallah Alenizi Department of Dermatology, Northern Border University, Arar, Saudi Arabia
Abstract
Adalimumab is a human monoclonal antibody that selectively targets tumour necrosis factor-alpha (TNF- a), a cytokine involved in the pathogenesis of various inaflmmatory and autoimmune disorders. Adalimumab has been approved worldwide for the treatment of several chronic immune-mediated diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. One of the adverse reactions caused by Adalimumab is psoriasis. This study reports the case of a 37-year-old male with palmoplantar psoriasis triggered by adalimumab for treatment of Crohn's disease. This eruption resisted complete clearance with various potent corticosteroids. The patient was referred back to the treating rheumatologist to possibly change adalimumab to another type of therapy.
Publication Details
Page(s) 1361-1363
Published Journal: Journal of Pakistan Medical Association, Volume: 74, Issue: 7, Year: 2024

Request the full text from PASTIC

Keywords
Psoriasis, Psoriasis, Crohn's disease, Adalimumab, paradoxical psoriasis
0

Citations

0

Downloads

74

Views